Ariosto S Silva
Overview
Explore the profile of Ariosto S Silva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1047
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bishop R, Li T, Sudalagunta P, Nasr M, Nyman K, Alugubelli R, et al.
Haematologica
. 2024 Dec;
PMID: 39633543
Multiple myeloma (MM) patients are often refractory to targeted therapies including proteasome inhibitors (PIs). Here, analysis of RNA sequencing data derived from 672 patients with newly diagnosed or relapsed/refractory disease...
2.
Sudalagunta P, Canevarolo R, Meads M, Silva M, Zhao X, Cubitt C, et al.
Cancer Res
. 2024 Oct;
85(2):378-398.
PMID: 39476082
Several therapeutic agents have been approved for treating multiple myeloma, a cancer of bone marrow-resident plasma cells. Predictive biomarkers for drug response could help guide clinical strategies to optimize outcomes....
3.
Li L, Hu X, Nkwocha J, Kmieciak M, Meads M, Shain K, et al.
Br J Haematol
. 2024 Oct;
205(6):2338-2348.
PMID: 39379134
Mechanisms underlying potentiation of the anti-myeloma (MM) activity of ataxia telangiectasia Rad3 (ATR) antagonists by MAPK (Mitogen-activated protein kinases)-related extracellular kinase 1/2 (MEK1/2) inhibitors were investigated. Co-administration of the ATR...
4.
Burger K, Fernandez M, Meads M, Sudalagunta P, Oliveira P, Canevarolo R, et al.
Cancer Res
. 2023 Sep;
83(23):3901-3919.
PMID: 37702657
Significance: CK1δ and CK1ε are attractive therapeutic targets in multiple myeloma whose expression increases with disease progression and connote poor outcomes, and that are necessary to sustain expression of genes...
5.
Tantawy M, Yang G, Algubelli R, DeAvila G, Rubinstein S, Cornell R, et al.
Front Cardiovasc Med
. 2023 Jul;
10:1181806.
PMID: 37408649
Background: Proteasome inhibitor Carfilzomib (CFZ) is effective in treating patients with refractory or relapsed multiple myeloma (MM) but has been associated with cardiovascular adverse events (CVAE) such as hypertension, cardiomyopathy,...
6.
Morris B, Smith J, Zhang Q, Jiang Z, Hampton O, Churchman M, et al.
Biomolecules
. 2022 Nov;
12(11).
PMID: 36358918
In the past decade, defective DNA repair has been increasingly linked with cancer progression. Human tumors with markers of defective DNA repair and increased replication stress exhibit genomic instability and...
7.
Jiang Q, Sudalagunta P, Silva M, Canevarolo R, Zhao X, Ahmed K, et al.
Bioinformatics
. 2022 Jun;
38(16):4002-4010.
PMID: 35751591
Motivation: Time-lapse microscopy is a powerful technique that relies on images of live cells cultured ex vivo that are captured at regular intervals of time to describe and quantify their...
8.
Peres L, Colin-Leitzinger C, Teng M, Dutil J, Alugubelli R, DeAvila G, et al.
Blood Adv
. 2022 May;
6(12):3767-3778.
PMID: 35500227
Multiple myeloma (MM) incidence, mortality, and survival vary by race and ethnicity, but the causes of differences remain unclear. We investigated demographic, clinical, and molecular features of diverse MM patients...
9.
Mostofa A, Distler A, Meads M, Sahakian E, Powers J, Achille A, et al.
JCI Insight
. 2021 Nov;
6(24).
PMID: 34793338
The clinical utility of histone/protein deacetylase (HDAC) inhibitors in combinatorial regimens with proteasome inhibitors for patients with relapsed and refractory multiple myeloma (MM) is often limited by excessive toxicity due...
10.
Zhou L, Zhang Y, Meads M, Dai Y, Ning Y, Hu X, et al.
Blood Adv
. 2021 Aug;
5(19):3776-3788.
PMID: 34464977
Interactions between the inhibitor of apoptosis protein antagonist LCL161 and the histone deacetylase inhibitor panobinostat (LBH589) were examined in human multiple myeloma (MM) cells. LCL161 and panobinostat interacted synergistically to...